CytoMed Therapeutics Limited (GDTC)
NASDAQ:GDTC
Want to see GDTC full AI Analyst Report?
GDTC Stock Chart & Stats
$1.39
-$0.41(-13.85%)
At close: 4:00 PM EST
$1.39
-$0.41(-13.85%)
Day’s Range― - ―
52-Week Range$0.73 - $3.68
Previous CloseN/A
Volume107.31K
Average Volume (3M)166.79K
Market Cap
$11.80M
Enterprise Value$10.10M
Total Cash (Recent Filing)$2.10M
Total Debt (Recent Filing)$482.56K
Price to Earnings (P/E)―
Beta0.21
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding11,832,835
10 Day Avg. Volume104,297
30 Day Avg. Volume166,789
Financial Highlights & Ratios
PEG Ratio-0.08
Price to Book (P/B)2.38
Price to Sales (P/S)62.86
P/FCF Ratio-3.55
Enterprise Value/Market Cap0.86
Enterprise Value/Revenue30.03
Enterprise Value/Gross Profit-41.97
Enterprise Value/Ebitda-3.06
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Improved Capitalization / Lower LeverageThe company reduced leverage materially versus 2020–2022 and maintains sizable equity relative to assets in 2023–2025. Lower leverage reduces near-term refinancing risk and gives management more optionality to fund R&D or operations without immediate debt pressure, supporting runway durability.
Owned Production Facilities In RegionOwnership of five production properties and low-cost regional infrastructure provides durable fixed-asset capacity and lowers ongoing manufacturing costs. This tangible asset base supports scalable clinical/commercial activity in Southeast Asia and can be monetized or used as collateral to extend operating runway.
Advancing Clinical Platform And PartnershipsProgressing a Phase I CAR‑T trial, escalating dose, launching a multi-site gamma delta T cell trial, and contributing to MD Anderson preclinical work strengthen the company’s R&D momentum and platform credibility. These durable clinical advances expand future commercialization potential and scientific partnerships.
Bears Say
Persistent Negative Cash Flow / Cash BurnConsistent negative operating and free cash flows and an intensifying cash burn in 2025 create ongoing dependency on external financing. Over a multi-month horizon this raises execution risk for trials and expansion, and increases the likelihood of dilutive financing or asset sales to maintain operations.
Ongoing Operating And Net Losses; Weak MarginsRecurrent operating and net losses with negative gross profit in 2025 signal deteriorating unit economics and limited internal ability to fund growth. Persistent negative margins limit reinvestment capacity and lengthen time to breakeven, requiring continued external capital or major operational restructuring.
Near-term Dilution Risk From Share Issuance MandateA proposed broad authority to issue shares and instruments signals likely near-term reliance on equity financing given weak cash balances. Structural dilution risk can erode existing shareholder value and complicate long-term return prospects, especially if capital is used to cover operating losses rather than value-accretive milestones.
CytoMed Therapeutics Limited News
GDTC FAQ
What was CytoMed Therapeutics Limited’s price range in the past 12 months?
CytoMed Therapeutics Limited lowest stock price was $0.73 and its highest was $3.68 in the past 12 months.
What is CytoMed Therapeutics Limited’s market cap?
CytoMed Therapeutics Limited’s market cap is $11.80M.
When is CytoMed Therapeutics Limited’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were CytoMed Therapeutics Limited’s earnings last quarter?
Currently, no data Available
Is CytoMed Therapeutics Limited overvalued?
According to Wall Street analysts CytoMed Therapeutics Limited’s price is currently Overvalued.
Does CytoMed Therapeutics Limited pay dividends?
CytoMed Therapeutics Limited does not currently pay dividends.
What is CytoMed Therapeutics Limited’s EPS estimate?
CytoMed Therapeutics Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does CytoMed Therapeutics Limited have?
CytoMed Therapeutics Limited has 11,832,835 shares outstanding.
What happened to CytoMed Therapeutics Limited’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of CytoMed Therapeutics Limited?
Currently, no hedge funds are holding shares in GDTC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
CytoMed Therapeutics Limited
CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers. The company's lead product candidate is CTM-N2D, which consists of expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor to improve anti-cancer cytotoxicity. It is also developing iPSC-gdNKT, which utilizes iPSC as a starting material to generate gdNKT, a synthetic hybrid of a gamma delta T cell and a NK cell; and CTM-GDT, a product candidate that consists of expanded gamma delta T cells, and exploits the multiple recognition system of gamma delta T cell to recognize and treat a range of cancers. The company was incorporated in 2018 and is headquartered in Singapore.
Technical Analysis
Ownership Overview
20.18% Insiders
0.04% Mutual Funds
0.19% Other Institutional Investors
79.59% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---